Becton, Dickinson and Company (NYSE:BDX) Shares Sold by First National Bank of Mount Dora Trust Investment Services

First National Bank of Mount Dora Trust Investment Services reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,870 shares of the medical instruments supplier’s stock after selling 2,911 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Becton, Dickinson and Company were worth $933,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the third quarter valued at about $26,000. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter valued at about $45,000. Abound Wealth Management grew its stake in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $0.07 during mid-day trading on Monday, hitting $235.31. The company’s stock had a trading volume of 331,553 shares, compared to its average volume of 1,366,898. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $68.01 billion, a P/E ratio of 48.40, a P/E/G ratio of 1.75 and a beta of 0.43. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The stock’s fifty day moving average price is $237.56 and its two-hundred day moving average price is $235.09.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.96 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on BDX. Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.